0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV322.54%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma1.42Leverage Ratio--Theta--Rho--Eff Leverage--Vega
MediciNova Stock Discussion
Medicinova - Gets Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for Treating Chlorine-Induced Acute Respiratory Distress Syndrome
NEWS
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
Medicinova Receives Issue Notification for New Patent Covering Extended-Release Formulations of Mn-166 (Ibudilast)
WSJ· 2 mins ago
MediciNova Secures Notice Of Grant For New Patent Covering MN-166 (Ibudilast) For Treatment Of Macular Injury In China
In reaction to earnings/guidance:
• $The Trade Desk(TTD.US)$+17%, $Workiva(WK.US)$ +15.3%, $Arlo Technologies(ARLO.US)$ +12%, $Array Technologies(ARRY.US)$ +10.3%, $Everbridge(EVBG.US)$ +9.7%, $Catalyst Pharmaceuticals(CPRX.US)$ +9.4%, $Halozyme Therapeutics(HALO.US)$ +8.7%, $Velo3D(VLD.US)$ +7.6%, $CyberArk(CYBR.US)$ + 6.2%, $Haemonetics(HAE.US)$ +5.8%, $Jackson Financial(JXN.US)$ +5.7% (also increases dividend), $Axon Enterprise(AXON.US)$ +4.8%,...
No comment yet